TAHO Pharmaceuticals Ltd is a Taiwan-based specialty pharmaceutical company engaged in the research, development, and commercialization of innovative drug delivery systems and 505(b)(2) reformulations of approved therapeutics. Founded in 2010 and headquartered in Taipei, Taiwan, the company focuses on improving patient compliance, bioavailability, and drug safety profiles across oncology supportive care, central nervous system disorders, and pain management. TAHO Pharmaceuticals operates through proprietary technology platforms, including its Oral Dissolving Film (ODF) platform, Transdermal Drug Delivery Systems (TDDS), and specialized mucosal absorption technologies. The company's core product portfolio and service offerings comprise TAHO-8801, an aprepitant oral dissolving film formulated for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV); TAHO-4411, a transdermal patch formulation designed for antiemetic therapy; proprietary oral thin films and hydrogel/matrix patches targeting neurological conditions, cardiovascular diseases, and acute pain indications; pharmaceutical contract formulation development and optimization services; preclinical and clinical-stage development services; and intellectual property licensing and commercial rights partnerships for international markets. TAHO Pharmaceuticals serves healthcare institutions, commercial distributors, and multinational biopharmaceutical partners across Taiwan, the wider Asia-Pacific region, and North America. In recent developments, the company has advanced its clinical and regulatory milestones by pursuing 505(b)(2) New Drug Application pathways with the United States Food and Drug Administration (FDA) and regulatory filings with the Taiwan Food and Drug Administration (TFDA) for its lead oral thin film programs. In addition, the company has broadened its international presence through strategic out-licensing and co-development alliances with regional pharmaceutical partners, while expanding commercial-scale supply agreements with certified current Good Manufacturing Practice (cGMP) manufacturing facilities to support market launch readiness for its proprietary film and transdermal dosage forms.